Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Melton B. Affrime"'
Publikováno v:
Pediatric Asthma, Allergy & Immunology. 19:146-153
Current treatment guidelines recommend intranasal corticosteroids or nonsedating antihistamines as first-line therapy for allergic rhinitis (AR). Because of concerns regarding the systemic safety of intranasal corticosteroids in children, the present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc7f3c6b65f5a162a8977cc154d19be8
https://doi.org/10.1089/pai.2006.19.146
https://doi.org/10.1089/pai.2006.19.146
Publikováno v:
British Journal of Clinical Pharmacology. 56:131-134
Aims To assess the single-dose pharmacokinetics and tolerability of pegylated interferon-α2b (PEG-Intron) in young and elderly healthy subjects. Methods In this parallel-design study, a single 1 µg kg−1 PEG-Intron dose was given subcutaneously to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4782b08f352ba2a647dc5b4a913d359b
https://doi.org/10.1046/j.1365-2125.2003.01836.x
https://doi.org/10.1046/j.1365-2125.2003.01836.x
Autor:
Samir K. Gupta, Sheila Jacobs, Suzanne K. Swan, Amy L. Pittenger, Melton B. Affrime, Emlyn Tobillo, Thomas Marbury, Vijay Batra, Paul Glue, Marshall Sack
Publikováno v:
The Journal of Clinical Pharmacology. 42:1109-1115
This study evaluates the pharmacokinetics and safety of pegylated interferon-alpha2b (PEG-Intron) following a single-dose subcutaneous injection into subjects with normal renal function, subjects with chronic renal impairment, and patients on hemodia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39fdf3abf3d0213cc8b68dbddb04f667
https://doi.org/10.1177/009127002237996
https://doi.org/10.1177/009127002237996
Autor:
Melton B. Affrime, J. Jen, Paul Glue, Carol Chung, Gerald Hajian, Mark Laughlin, Samuel Heft, Samir K. Gupta
Publikováno v:
Clinical Pharmacology & Therapeutics. 72:349-361
Background Combination therapy of ribavirin with interferon alfa-2b and pegylated interferon alfa-2b is currently approved for the treatment of chronic hepatitis C. Approved ribavirin dosages vary from a fixed dosage of 800 mg/d to as much as 1200 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f53d8f35d52d75eb73b4988bd75c53
https://doi.org/10.1067/mcp.2002.127112
https://doi.org/10.1067/mcp.2002.127112
Autor:
Vijay Batra, James E. Patrick, Bo Yang, L. Mellars, Melton B. Affrime, Enrico P. Veltri, Teddy Kosoglou, Yali Zhu, David L. Cutler, Stephen E. Maxwell, Paul Statkevich, Ingo Meyer
Publikováno v:
British Journal of Clinical Pharmacology. 54:309-319
Aims The primary aims of these two single-centre, randomized, evaluator-blind, placebo/positive-controlled, parallel-group studies were to evaluate the potential for pharmacodynamic and pharmacokinetic interaction between ezetimibe 0.25, 1, or 10 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f9460a8093805cd2bbf3c21aa4338b5
https://doi.org/10.1046/j.1365-2125.2002.01633.x
https://doi.org/10.1046/j.1365-2125.2002.01633.x
Publikováno v:
Clinical Pharmacokinetics. 41:37-44
Objective: This study was performed to assess the electrocardiographic safety and pharmacokinetics of desloratadine in combination with the CYP3A4 inhibitor ketoconazole. Design: A randomised, placebo-controlled, third-party—blind, 2-way crossover
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d75c84952ee69b184ca2acc159799e
https://doi.org/10.2165/00003088-200241001-00006
https://doi.org/10.2165/00003088-200241001-00006
Publikováno v:
Clinical Pharmacokinetics. 41:13-19
Objective: To characterise the pharmacokinetic profile of desloratadine and its main metabolite, 3-hydroxy (3-OH) desloratadine, in a patient population representative of the population studied in the desloratadine clinical efficacy and safety studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295c731f7f22b2523b72a1fc674a878a
https://doi.org/10.2165/00003088-200241001-00003
https://doi.org/10.2165/00003088-200241001-00003
Publikováno v:
Clinical Pharmacokinetics. 41:311-318
Certain foods, such as grapefruit juice, are known to substantially alter the bioavailability of some drugs. These effects may be mediated by interactions with enzyme systems, such as cytochrome P450, or with active transporter systems, such as P-gly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b115476f034a420fa5dad86ba00a64
https://doi.org/10.2165/00003088-200241040-00004
https://doi.org/10.2165/00003088-200241040-00004
Autor:
Samir K. Gupta, Christopher Banfield, Bhavna Kantesaria, Mark Marino, Melton B. Affrime, Robert P. Clement, Vijay Batra
Publikováno v:
Clinical Therapeutics. 23:451-466
Significant cardiac toxicity has been associated with some older antihistamines (eg, terfenadine and astemizole) when their plasma concentrations are increased. There is thus a need for a thorough assessment of the cardiac safety of newer antihistami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950237b6e5af52a7cb5cb5e42eb5e57b
https://doi.org/10.1016/s0149-2918(01)80049-7
https://doi.org/10.1016/s0149-2918(01)80049-7
Autor:
Rachel Bacon, Stephen P. Newman, Mark Marino, Melton B. Affrime, G.R. Pitcairn, Peter H. Hirst, Hannah Pickering
Publikováno v:
Clinical Therapeutics. 22:1483-1493
Background: A new inhaled suspension formulation of mometasone furoate (MF), a potent corticosteroid with minimal systemic availability, has been developed for the treatment of asthma. This formulation is delivered by metered-dose inhaler (MDI) using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edeefac0c83fb59cd61775012066763f
https://doi.org/10.1016/s0149-2918(00)83046-5
https://doi.org/10.1016/s0149-2918(00)83046-5